Global Surgical Glue Market is expected to register a healthy CAGR in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period is 2018 to 2025.Access Full Report: https://databridgemarketresearch.com/reports/global-surgical-glue-market/
The global surgical glue market highly concentrated to a few big players and rest to local players who cater to domestic markets only. The global surgical glue market is dominated by Baxter, Cardinal Health, B. Braun Melsungen AG and Medtronic.
Founded in 1931 and headquartered in Illinois, U.S. Baxter is focused in is focused on providing acute and chronic dialysis therapies; sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anaesthetics; generic injectable pharmaceuticals; and surgical hemostat and sealant products. The company operates in renal care, medication delivery, pharmaceuticals, nutrition, advanced surgery, acute therapies and others. Surgical glue products are available in advanced surgery business segment
There are various subsidiaries of the company worldwide. Some of them are Baxter S.p.A. (Italy), Gambro (Sweden), Baxter Argentina S.A. (Argentina), Baxalta Innovations GmbH (Germany), Baxter India Private Limited (India) and among others. The company has its presence in U.S., Latin America, Canada, Europe and Asia Pacific. In January, Baxter International Inc. received an approval from U.S. Food and Drug Administration for its product Tisseel. It has applications in general hemostasis in surgery to control blood loss during the surgical procedures. The product controls bleeding by creating a clot that adheres to the wound surface and helps in hemostasis. This addition to the product portfolio is an effective tool for surgeons in controlling bleeding for a wide variety of surgical procedures.
Founded in 1979 and headquartered in Ohio, U.S. The company focuses on offering the integrated healthcare services and products worldwide. The company operates in 2 business segments; medical and pharmaceutical. The company offers surgical product in the medical segment. The company obtained the CE Mark Certification in EU market for medical devices.
The company subsidiaries are Cardinal Health Medical Products India Private Limited (India), Cardinal Health Norway AS (Norway), Cardinal Health Spain 511 S.L (Spain), Griffin Capital, LLC (U.S.), Cardinal Health Germany 234 GmbH (Germany) and among others. The company has its presence in Europe, Asia-Pacific region and America region.
Founded in 1839 and headquartered in Melsungen, Germany, B. Braun Melsungen AG is focused on developing effective solutions and trend setting standards in 18 therapy fields of the health care industry. The company has 4 business segments. They are Hospital Care, Avitum, Aesculap and Outpatient Market. The surgical glue products are offered by the company in their Aescucalp business segment. The product categories of the company include Continence Care & Urology, Diabetes Care, Extracorporeal blood treatment, Infection Prevention, Infusion, Interventional Vascular Diagnostics & Therapy, IV Drugs, Neurosurgery, Nutrition, Orthopaedic Joint Replacement, Ostomy Care, Regional Anesthesia, Spine Surgery, Surgical Technologies, Wound Closure, Wound Management and others.
The company subsidiaries include Aesculap (U.S.), B. Braun Medical Inc. (U.S.), B. Braun Medical (India) Pvt. Ltd. (India), B. Braun of America, Inc. (U.S.), Saxonia Medical Gmbh (Germany) and among others. The company has its presence in Germany, Europe (without Germany), North America, Asia Pacific, Latin America, Middle East and Africa. In January, Novation, LLC (U.S.), the University HealthSystem Consortium (UHC) (U.S.) and Provista, LLC (U.S.) have given supplier contract to Aesculap, Inc. for its Histoacryl tissue adhesive products. Aesculap is a subsidiary of B. Braun and has a reputation of providing quality valur products to the surgical industry. Histoacryl is FDA approved and provides highest bond strength in a single application. This agreement shows Aesculap’s commitment and competitiveness in providing best quality products.